BriaCell Therapeutics (OTCMKTS:BCTXF) versus AbbVie (NYSE:ABBV) Head-To-Head Review

AbbVie (NYSE:ABBV) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for AbbVie and BriaCell Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0	5	17	2	2.88
BriaCell Therapeutics	0	0	0	0	0.00

AbbVie currently has a consensus price target of $203.65, indicating a potential upside of 17.47%. Given AbbVie’s stronger consensus rating and higher probable upside, equities research analysts clearly believe AbbVie is more favorable than BriaCell Therapeutics.

Volatility and Risk

AbbVie has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Earnings and Valuation

This table compares AbbVie and BriaCell Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$54.32 billion	5.64	$4.86 billion	$2.88	60.20
BriaCell Therapeutics	N/A	N/A	-$3.68 million	($3.84)	-1.55

AbbVie has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbbVie and BriaCell Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AbbVie	9.22%	244.01%	13.44%
BriaCell Therapeutics	N/A	N/A	-786.77%

Insider and Institutional Ownership

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 0.1% of BriaCell Therapeutics shares are owned by institutional investors. 0.3% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

AbbVie beats BriaCell Therapeutics on 13 of the 14 factors compared between the two stocks.

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

About BriaCell Therapeutics

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.